For third consecutive year, MMI will highlight its pioneering role in the field of robotic microsurgery

MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place in San Francisco from January 13-16, 2025. This marks MMI’s third consecutive year presenting in the private company track, underscoring sustained interest in groundbreaking advancements and innovations within the field of open surgery.

Mark Toland, Chief Executive Officer of MMI, will deliver a presentation on Tuesday, January 14, at 9:30 AM PST at the Westin St. Francis Hotel, Mission Bay meeting room. He will discuss the transformative impact of microsurgical robotics and highlight the global commercial and clinical advancements of the Symani^® Surgical System in 2024.

In 2024, the U.S. Food and Drug Administration (FDA) granted De Novo Classification to Symani, making it the only commercially available platform in the U.S. for reconstructive microsurgery. Leveraging momentum from regulatory approvals in over 35 countries, MMI achieved strong growth, more than doubling its install base compared to 2023. The first-of-its-kind technology, featuring the world’s smallest wristed robotic instruments for less invasive soft tissue surgery, is benefiting cancer and lymphedema patients worldwide.

The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, connecting global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

For more information on the J.P. Morgan Healthcare Conference, visit https://www.jpmorgan.com/about-us/events-conferences/health-care-conference.

To learn more about MMI, visit http://mmimicro.com.

About MMI

MMI (Medical Microinstruments, Inc.) is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani^® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair. In Europe, it also addresses peripheral nerve repair. The Symani System is authorized for use in the U.S. by the FDA, is a CE Marked medical device in Europe, and has received approval from several APAC regulatory bodies. MMI is backed by global investors including Fidelity Management & Research Company, Andera Partners, BioStar, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250108435577/en/